Clinical trial
A Phase I Study of Pazopanib in Adult Patients With Liver Cancer
NCT00370513 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00370513 |
|---|---|
| Title | A Phase I Study of Pazopanib in Adult Patients With Liver Cancer |
| Official title | A Phase I, Open-Label, Dose-Escalation, Multi-Center Study or Pazopanib (GW786034) in Adult Patients With Hepatocellular Cancer |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Carcinoma, Hepatocellular |
| Intervention type | Drug |
| Interventions | pazopanib |
| Enrollment | 28 |
| Start date | Dec 6, 2006 |
| Primary completion | Apr 8, 2009 |
| Completion | Apr 8, 2009 |
| First posted | Aug 31, 2006 |
| Last update posted | Nov 17, 2017 |
| Countries | Hong Kong, Taiwan, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: